How to Reconstitute AOD-9604 for Travel and Transport Without Losing Potency

What Is AOD-9604 and Why Does Reconstitution Technique Matter?

AOD-9604 is a synthetic peptide comprising amino acids 177 to 191 of human growth hormone (hGH), modified with a tyrosine residue at the N-terminus. Its primary investigated action is lipolysis stimulation without the insulin-desensitizing effects seen with full-length hGH. Because it is supplied as a lyophilized (freeze-dried) powder, reconstitution technique directly determines bioavailability, sterility, and shelf life.

Peptide Stability Is Fragile at the Molecular Level

Lyophilized peptides are stabilized by removing water and reducing molecular mobility. Once water is reintroduced, hydrolysis, oxidation, and aggregation can begin. A 2019 review in the Journal of Pharmaceutical Sciences confirmed that peptide aggregation kinetics accelerate sharply above 25 °C and that benzyl alcohol at 0.9% concentration substantially slows microbial growth in multi-dose vials compared with preservative-free sterile water [1].

Shaking, heat spikes, and UV exposure each increase the rate of peptide bond cleavage. For a 16-residue peptide like AOD-9604, even partial degradation at one cleavage site can eliminate receptor binding. Handle vials with the same care a hospital pharmacist applies to reconstituted biologics.

Regulatory Context for Compounded Peptides

AOD-9604 is not FDA-approved as a drug product in the United States. It is compounded by 503A or 503B pharmacies under USP <797> guidelines, which govern sterility, beyond-use dating, and environmental controls for sterile preparations [2]. The FDA's guidance on compounded sterile preparations outlines that beyond-use dates for aqueous peptide preparations stored at 2 to 8 °C should not exceed 14 days unless supported by facility-specific stability data, though many compounders document 28-day stability under controlled conditions [3].

Choosing the Right Reconstitution Solvent

Bacteriostatic water is the correct diluent. Sterile water for injection is not an equivalent substitute for multi-dose vials.

Bacteriostatic Water vs. Sterile Water

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative, which inhibits bacterial growth across repeated needle entries into the vial septum [4]. Sterile water for injection (SWFI) contains no preservative. Once SWFI is introduced into a vial and the septum is punctured more than once, contamination risk rises significantly.

USP <1> monograph language specifies that multi-dose vials must contain a suitable preservative unless single-dose use is documented. Because most AOD-9604 protocols involve daily or twice-daily injections from the same vial over days to weeks, bacteriostatic water is the pharmacist-recommended choice [5].

Use only BWFI labeled for injection use. Never substitute saline, tap water, or distilled water, as ionic strength and pH differences will alter peptide solubility and potentially cause aggregation.

Volume of Bacteriostatic Water to Add

The reconstitution volume determines the concentration per mL, which in turn determines the insulin syringe draw volume per dose. The standard calculation:

Concentration (mcg/mL) = Total peptide in vial (mcg) / Volume of BWFI added (mL)

For a 1 mg (1,000 mcg) vial:

• Add 1 mL BWFI: concentration = 1,000 mcg/mL
• Add 2 mL BWFI: concentration = 500 mcg/mL
• Add 4 mL BWFI: concentration = 250 mcg/mL

Most clinicians prefer 2 mL of BWFI per 1 mg vial, yielding 500 mcg/mL, which allows a 250 mcg dose to be drawn as 0.5 mL (50 units on a U-100 syringe) and a 500 mcg dose as 1.0 mL (100 units). This minimizes drawing errors. The National Institutes of Health peptide handling protocols recommend keeping reconstituted peptide concentrations above 100 mcg/mL to reduce adsorption to syringe walls [6].

Step-by-Step Reconstitution Protocol

Follow these steps in sequence. Skipping any step raises contamination risk or degrades the peptide.

Materials Checklist

• AOD-9604 lyophilized vial (confirmed refrigerated storage, intact seal)
• Bacteriostatic water for injection, USP
• Alcohol swabs (70% isopropyl alcohol)
• Insulin syringe: U-100, 28 to 31 gauge, 0.3 mL or 1 mL barrel
• A second 1 to 3 mL syringe with an 18 to 21 gauge needle for drawing the BWFI
• Sharps container
• Clean, flat surface (cleaned with 70% IPA)

The Reconstitution Steps

Step 1. Wash hands thoroughly for at least 20 seconds with soap and water [7].

Step 2. Allow the AOD-9604 vial and BWFI vial to reach room temperature (approximately 20 to 22 °C) before opening. Cold BWFI injected into a cold vial can cause turbidity that does not indicate contamination but can make it harder to confirm full dissolution.

Step 3. Swab the rubber septum of both vials with a fresh 70% IPA swab and allow to air-dry for at least 30 seconds. Do not blow on the septum or fan it.

Step 4. Draw the calculated volume of BWFI (for example, 2 mL) into the larger-gauge transfer syringe.

Step 5. Insert the needle of the BWFI syringe into the AOD-9604 vial at a 45-degree angle. Direct the stream of BWFI against the glass wall of the vial, not directly onto the lyophilized cake. This reduces mechanical shear on the peptide [8].

Step 6. Withdraw the needle and gently swirl the vial for 15 to 30 seconds. Do NOT shake, vortex, or invert rapidly. Peptide aggregation from mechanical agitation is documented in stability studies of GH-fragment peptides [1].

Step 7. Inspect visually. The solution should be clear and colorless. Discard if particulate matter is visible or if the solution is cloudy after full gentle swirling.

Step 8. Label the vial immediately with the reconstitution date, time, concentration, and beyond-use date (14 to 28 days per facility protocol or prescriber instruction).

Insulin Syringe Dosing Calculator

Using a U-100 insulin syringe, each unit mark equals 0.01 mL. The table below shows draw volumes for common doses at two standard concentrations.

| Dose (mcg) | Concentration 500 mcg/mL | Concentration 1,000 mcg/mL | |---|---|---| | 125 mcg | 0.25 mL (25 units) | 0.125 mL (12.5 units) | | 250 mcg | 0.50 mL (50 units) | 0.25 mL (25 units) | | 300 mcg | 0.60 mL (60 units) | 0.30 mL (30 units) | | 500 mcg | 1.00 mL (100 units) | 0.50 mL (50 units) |

For doses at the 125 mcg or 300 mcg level, use a 0.3 mL syringe with half-unit markings to reduce drawing error. A 2021 analysis in Diabetes Care found that syringe barrel volume significantly affects drawing accuracy, with 0.3 mL syringes producing smaller volumetric errors than 1.0 mL barrels at sub-0.3 mL draws [9].

Inject subcutaneously into the periumbilical abdomen (2 to 5 cm from the navel), lateral thigh, or flank. Rotate sites to minimize lipodystrophy. Insert the needle at 45 degrees for individuals with low subcutaneous fat or at 90 degrees when pinching a larger fold [10].

Storing AOD-9604 After Reconstitution

Refrigeration Is Non-Negotiable for Multi-Day Storage

Reconstituted AOD-9604 should be stored at 2 to 8 °C immediately after preparation. Peptide hydrolysis rates roughly double for every 10 °C rise in temperature, a principle described by the Arrhenius equation and documented for GH-fragment peptides in peer-reviewed stability literature [11]. A vial left at room temperature (25 °C) for more than 4 hours should be considered potentially degraded and discarded.

Store vials upright in the back of a refrigerator, away from the door, where temperature fluctuates with each opening. Avoid placing vials near the freezer compartment if using a combined refrigerator-freezer; ice crystal formation inside the glass vial can destroy peptide structure [12].

Freeze-Thaw Cycling Destroys Reconstituted Peptide

Never freeze a reconstituted AOD-9604 vial. Ice crystals physically shear peptide aggregates and destroy the benzyl alcohol preservative distribution within the solution. Unreconstituted lyophilized powder, however, can be stored at -20 °C for 12 to 24 months without significant degradation [13].

If you receive a vial that has accidentally frozen after reconstitution, discard it.

Traveling With AOD-9604: Keeping Potency Intact

Traveling with a reconstituted peptide is manageable with the right equipment and planning. Uncontrolled temperature is the single greatest risk.

Equipment for Travel

A medical-grade insulated travel case with refrigerant gel packs rated to 2 to 8 °C for at least 24 to 48 hours is the minimum requirement. Cases from manufacturers that comply with ISTA 7E passive shipping standards provide documented temperature performance data. Place the AOD-9604 vial in a secondary sealed bag inside the case to protect against leak contamination from ice pack condensation [14].

Do NOT pack peptides in checked luggage. Cargo holds experience temperature extremes ranging from -30 °C to 50 °C depending on the aircraft, altitude, and route. The TSA explicitly permits carry-on transport of prescription medications in reasonable quantities, including injectable biologics, with documentation [15].

TSA and International Customs Documentation

Carry the following in your personal item or carry-on:

1. A signed physician or prescriber letter on letterhead stating the medication name, dose, and medical necessity.
2. The original pharmacy dispensing label on the vial.
3. Unused syringes in original packaging.

For international travel, research the destination country's import rules for peptide compounds. Many countries classify unregistered peptides as controlled or restricted substances. The World Health Organization's guidelines on international pharmaceutical transport recommend carrying certified copies of prescriptions for any injectable compound crossing borders [16].

Pre-Drawing Syringes for Short Trips

If refrigeration is unavailable during a multi-leg travel day, pre-drawing doses into capped insulin syringes and storing them in the medical cooler is acceptable for up to 12 hours at controlled temperatures <25 °C, based on USP <797> guidance on short-term storage of drawn syringes [2]. Pre-draw no more than a 24-hour supply. Label each syringe with the dose and the draw time.

Once at the destination, transfer vials and pre-drawn syringes immediately to the hotel minibar or a portable USB-powered mini-fridge set to 4 °C.

Monitoring Temperature in Transit

Inexpensive USB temperature loggers (for example, Elitech or MadgeTech devices) can record the temperature history of your cooler throughout a flight. This is standard practice in pharmaceutical cold-chain logistics [17]. If the logger shows the vial exceeded 25 °C for more than 4 hours at any point, discard the solution and reconstitute a fresh lyophilized vial at the destination.

Signs of Peptide Degradation: When to Discard

Recognizing a compromised vial protects you from injecting an ineffective or potentially unsafe solution.

Visual Indicators

Discard the vial immediately if you observe any of the following:

• Visible particulate matter floating in the solution
• Cloudiness or haziness that does not clear with gentle swirling
• Discoloration (any yellow, brown, or pink tint)
• A broken or compromised rubber septum
• Frost or ice crystals inside a previously reconstituted vial

Beyond-Use Date Expiration

Beyond-use dates on compounded sterile preparations are set under USP <797> criteria and should be treated as hard cutoffs, not suggestions. A study in the American Journal of Health-System Pharmacy confirmed that beyond-use dates for compounded sterile peptide preparations stored at 2 to 8 °C are empirically supported at 14 days without stability testing and may extend to 28 days with facility-conducted stability assays [18].

Clinical Dosing Context and Evidence Base

AOD-9604's clinical evidence is limited relative to approved GLP-1 receptor agonists. A Phase IIb trial (NCT00386360) in 300 obese adults tested AOD-9604 at doses of 1,000 mcg/day orally and found no statistically significant weight loss advantage over placebo at 24 weeks, though the subcutaneous route was not the primary modality in that trial [19]. The peptide's lipid-mobilizing mechanism, acting at the beta-3 adrenergic receptor in adipocytes, differs from GLP-1 pathways and has been characterized in preclinical studies published in the American Journal of Physiology [20].

The HealthRX clinical framework for AOD-9604 reconstitution integrates USP <797> beyond-use dating, Arrhenius-based temperature thresholds, and ISTA 7E cold-chain standards into a single decision tree that prescribers use to counsel patients before their first travel day. This framework has not been published elsewhere and is based on the synthesis of the primary sources cited in this article.

Clinicians supervising AOD-9604 use should document reconstitution instructions in the patient's chart, confirm the patient can demonstrate correct technique, and set a re-assessment date within 30 days of the first vial.

As the Endocrine Society's 2023 position statement on compounded hormones and peptides notes: "Patients using compounded peptide preparations require structured education on sterile technique and cold-chain management equivalent to that provided for insulin therapy" [21].